•
Sep 30, 2021

DexCom Q3 2021 Earnings Report

Dexcom's revenue increased by 30% year-over-year, driven by volume growth and new customer additions. The company raised its full-year revenue and margin guidance.

Key Takeaways

Dexcom reported a strong third quarter with revenue growth of 30% year-over-year to $650.2 million. The company's GAAP operating income was $118.3 million, or 18.2% of revenue. Dexcom also raised its full-year revenue and margin guidance.

Revenue grew 30% versus the same quarter of the prior year to $650.2 million.

U.S. revenue growth of 23% and international revenue growth of 57%.

GAAP operating income of $118.3 million or 18.2% of revenue.

Completed the acquisition of our distributor in Australia and New Zealand.

Total Revenue
$650M
Previous year: $501M
+29.8%
EPS
$0.22
Previous year: $0.24
-8.3%
Gross margin
68.7%
Previous year: 68%
+1.0%
Operating margin
18.2%
Previous year: 18.8%
-3.2%
Gross Profit
$447M
Previous year: $340M
+31.3%
Cash and Equivalents
$1.44B
Previous year: $674M
+114.4%
Free Cash Flow
$139M
Previous year: $100M
+38.9%
Total Assets
$4.78B
Previous year: $3.83B
+24.6%

DexCom

DexCom

DexCom Revenue by Segment

DexCom Revenue by Geographic Location

Forward Guidance

Dexcom is increasing its guidance for fiscal year 2021 revenue, Non-GAAP gross profit margin, Non-GAAP operating margin, and Adjusted EBITDA margin.

Positive Outlook

  • Revenue of approximately $2.425 - 2.450 billion (26-27% growth; Growth includes approximately 1% from acquired revenue in conjunction with Dexcom’s acquisition of its distributor in Australia and New Zealand)
  • Non-GAAP Gross Profit Margin of approximately 68%
  • Non-GAAP Operating Margin of approximately 16%
  • Adjusted EBITDA Margin of approximately 25%

Revenue & Expenses

Visualization of income flow from segment revenue to net income